The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Prediction of Human Intestinal First-Pass Metabolism of 25 CYP3A Substrates from In Vitro Clearance and Permeability Data
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Some suggestions for measuring predictive performance
Sheiner, L. B., & Beal, S. L. (1981) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01060893 · Cited by 1,617
Obach, R. S. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14938-0 · Cited by 1,232
THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”
Paine, M. F., Hart, H. L., Ludington, S. S., Haining, R. L., Rettie, A. E., & Zeldin, D. C. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.008672 · Cited by 870
Pang, K. S., & Rowland, M. (1977) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059688 · Cited by 797
Paine, M. F., Khalighi, M., Fisher, J. M., Shen, D. D., Kunze, K. L., Marsh, C. L., Perkins, J. D., & Thummel, K. E. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37149-6 · Cited by 789
Rational Use of in Vitro P-glycoprotein Assays in Drug Discovery
Polli, J. W., Wring, S. A., Humphreys, J. E., Huang, L., Morgan, J. B., Webster, L. O., & Serabjit-Singh, C. S. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29270-3 · Cited by 662
Doan, K. M. M., Humphreys, J. E., Webster, L. O., Wring, S. A., Shampine, L. J., Serabjit-Singh, C. J., Adkison, K. K., & Polli, J. W. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.039255 · Cited by 614
Simulation and prediction of in vivo drug metabolism in human populations from in vitro data
Rostami-Hodjegan, A., & Tucker, G. T. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2173 · Cited by 530
Barter, Z., Bayliss, M., Beaune, P., Boobis, A., Carlile, D., Edwards, R., Brian Houston, J., Lake, B., Lipscomb, J., Pelkonen, O., et al. (2007) · Current Drug Metabolism · doi:10.2174/138920007779315053 · Cited by 459 · cited 1×
“40 mg of protein/g of liver (Barter et al., 2007) and a liver weight of 21.”
BackgroundWiniwarter, S., Bonham, N. M., Ax, F., Hallberg, A., Lennernäs, H., & Karlén, A. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm9810102 · Cited by 453
Population-Based Mechanistic Prediction of Oral Drug Absorption
Jamei, M., Turner, D., Yang, J., Neuhoff, S., Polak, S., Rostami-Hodjegan, A., & Tucker, G. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9099-y · Cited by 452
Sun, D., Lennernas, H., Welage, L. S., Barnett, J. L., Landowski, C. P., Foster, D., Fleisher, D., Lee, K.-D., & Amidon, G. L. (2002) · Pharmaceutical Research · doi:10.1023/a:1020483911355 · Cited by 447
Granger, D. N., Richardson, P. D. I., Kvietys, P. R., & Mortillaro, N. A. (1980) · Gastroenterology · doi:10.1016/0016-5085(80)90692-7 · Cited by 420
Riley, R. J., McGinnity, D. F., & Austin, R. P. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.004259 · Cited by 371
Prediction of Intestinal First-Pass Drug Metabolism
Yang, J., Jamei, M., Yeo, K., Tucker, G., & Rostami-Hodjegan, A. (2007) · Current Drug Metabolism · doi:10.2174/138920007782109733 · Cited by 366
Is the Role of the Small Intestine in First-Pass Metabolism Overemphasized?
Lin, J. H., Chiba, M., & Baillie, T. A. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01402-9 · Cited by 352
Eagling, V. A., Back, D. J., & Barry, M. G. (1997) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1997.00644.x · Cited by 333
Intestinal permeability and its relevance for absorption and elimination
Lennernäs, H. (2007) · Xenobiotica · doi:10.1080/00498250701704819 · Cited by 304
Ito, K., & Houston, J. B. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-9015-1 · Cited by 260
Self-citationKoudriakova, T., Iatsimirskaia, E., Utkin, I., Gangl, E. T., Vouros, P., Storozhuk, E., Orza, D., Marinina, J., & Gerber, N. (1998) · PubMed · Cited by 259
P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies.
Wandel, C., Kim, R. B., Kajiji, S. M., Guengerich, P. F., Wilkinson, G. R., & Wood, A. J. J. (1999) · PubMed · Cited by 249
Mechanism-Based Inactivation of CYP3A by HIV Protease Inhibitors
Ernest, C. S., Hall, S. D., & Jones, D. R. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.075416 · Cited by 246
pH‐Profile and regional transit times of the normal gut measured by a radiotelemetry device
FALLINGBORG, J., CHRISTENSEN, L. A., INGEMAN‐NIELSEN, M., JACOBSEN, B. A., ABILDGAARD, K., & RASMUSSEN, H. H. (1989) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.1989.tb00254.x · Cited by 241
Rostami-Hodjegan, A., & Tucker, G. (2004) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2004.10.002 · Cited by 239
Molecular and physical mechanisms of first-pass extraction.
Hall, S. D., Thummel, K. E., Watkins, P. B., Lown, K. S., Benet, L. Z., Paine, M. F., Mayo, R. R., Turgeon, D. K., Bailey, D. G., Fontana, R. J., et al. (1999) · PubMed · Cited by 235
Fahmi, O. A., Maurer, T. S., Kish, M., Cardenas, E., Boldt, S., & Nettleton, D. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.018663 · Cited by 204
PREDICTION OF CYTOCHROME P450 3A INHIBITION BY VERAPAMIL ENANTIOMERS AND THEIR METABOLITES
Wang, Y.-H., Jones, D. R., & Hall, S. D. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.2.259 · Cited by 200
Wu, X., Whitfield, L. R., & Stewart, B. H. (2000) · Pharmaceutical Research · doi:10.1023/a:1007525616017 · Cited by 189
EVIDENCE OF SIGNIFICANT CONTRIBUTION FROM CYP3A5 TO HEPATIC DRUG METABOLISM
Huang, W., Lin, Y. S., McConn, D. J., Calamia, J. C., Totah, R. A., Isoherranen, N., Glodowski, M., & Thummel, K. E. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.001313 · Cited by 175
Hallifax, D., & Houston, J. B. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.007658 · Cited by 173
Self-citationGaletin, A., & Houston, J. B. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.106013 · Cited by 160
Self-citationChiba, M., Hensleigh, M., & Lin, J. H. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00100-7 · Cited by 134
Potential role of intestinal first-pass metabolism in the prediction of drug–drug interactions
Galetin, A., Gertz, M., & Houston, J. B. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.7.909 · Cited by 124
Self-citationEffects of Intestinal CYP3A4 and P-Glycoprotein on Oral Drug Absorption—Theoretical Approach
Ito, K., Kusuhara, H., & Sugiyama, Y. (1999) · Pharmaceutical Research · doi:10.1023/a:1018872207437 · Cited by 123
Galetin, A., Gertz, M., & Houston, J. B. (2010) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.25.28 · Cited by 113
Self-citationSymposium Article: Molecular and Physical Mechanisms of First-Pass Extraction
Hall, S. D., Thummel, K. E., Watkins, P. B., Lown, K. S., Benet, L. Z., Paine, M. F., Mayo, R. R., Turgeon, D. K., Bailey, D. G., Fontana, R. J., et al. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15271-3 · Cited by 109
Interactions of Human P-glycoprotein with Simvastatin, Simvastatin Acid, and Atorvastatin
Hochman, J. H., Pudvah, N. T., Qiu, J., Yamazaki, M., Tang, C., Lin, J. H., & Prueksaritanont, T. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000041466.84653.8c · Cited by 109
Kato, M., Chiba, K., Hisaka, A., Ishigami, M., Kayama, M., Mizuno, N., Nagata, Y., Takakuwa, S., Tsukamoto, Y., Ueda, K., et al. (2003) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.18.365 · Cited by 91
Galetin, A., Brown, C., Hallifax, D., Ito, K., & Houston, J. B. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.000844 · Cited by 81
Self-citationGertz, M., Kilford, P. J., Houston, J. B., & Galetin, A. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.018713 · Cited by 78
Self-citationGertz, M., Davis, J. D., Harrison, A. C., Houston, J. B., & Galetin, A. (2008) · Current Drug Metabolism · doi:10.2174/138920008786049276 · Cited by 68
Self-citationBadhan, R. K. S., Penny, J. I., Galetin, A., & Houston, J. B. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21572 · Cited by 53
Self-citationThe effects of portal shunts on intestinal cytochrome P450 3A activity
Rostami‐Hodjegan, A., & Tucker, G. T. (2002) · Hepatology · doi:10.1053/jhep.2002.33215 · Cited by 38
Tam, D., Sun, H., & Pang, K. S. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.10.1214 · Cited by 35
Cited by
Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates
Doak, B. C., Over, B., Giordanetto, F., & Kihlberg, J. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.013 · Cited by 835
Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science
Rowland, M., Peck, C., & Tucker, G. (2011) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100540 · Cited by 662
Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development
Jones, H., & Rowland‐Yeo, K. (2013) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2013.41 · Cited by 626
PBPK models for the prediction of in vivo performance of oral dosage forms
Kostewicz, E. S., Aarons, L., Bergstrand, M., Bolger, M. B., Galetin, A., Hatley, O., Jamei, M., Lloyd, R., Pepin, X., Rostami-Hodjegan, A., et al. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.09.008 · Cited by 315
Self-citationCell permeability beyond the rule of 5
Matsson, P., Doak, B. C., Over, B., & Kihlberg, J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.03.013 · Cited by 297
Metadata
- Authors
- Gertz, M., Harrison, A., Houston, J. B., & Galetin, A.
- Venue
- Drug Metabolism and Disposition
- Publisher
- Elsevier BV
- Published
- 2010-07
- Volume
- 38
- Issue
- 7
- Pages
- 1147-1158
- ISSN
- 0090-9556 (ISSN-L)
- OpenAlex
- W2142573506
- Cited by
- 297
- References
- 44
- FWCI
- 19.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.